Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 51.83 · gapped above the open, then crossed back over prior close. High/low 53.50 at 7:00 am ET, 51.52 at 2:30 pm ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Collaboration revenue was $35.0 million for the year ended December 31, 2024 and was related to Vertex's achievement of a $10.0 million research milestone and $25.0 million research milestone under the Non-Ex License Agreement with Vertex in 2024.”
FILING10-K0001193125-26-048957cik 0001674416
“Further, our license and collaboration agreement with CRISPR provides us with certain propriety gene-editing technology, including the CRISPR/Cas platform, material to supporting the research, development and potential commercialization of ADI-212.”
FILING10-K0001720580-26-000008cik 0001720580disclosed by ACET
“In May 2025, we partnered with Sirius and entered into the Sirius Agreement pursuant to which, among other things, we and Sirius will collaborate on the research, development, manufacture, commercialization and use of the Sirius Collaboration Products, including co-development and co-commercialization of CTX611; and (2) Sirius granted us options to exclusively license Sirius siRNA technology to target up to two licensed targets from a list of seven reserved targets for the research, develop, manufacture and commercialization of siRNA Licensed Products”
FILING10-K0001193125-26-048957cik 0001674416
“We have advanced this technology from discovery to an approved medicine with unparalleled speed, culminating in the landmark first approval of a CRISPR-based therapy, CASGEVY (exagamglogene autotemcel [exa-cel]), in 2023 with our collaborators at Vertex Pharmaceuticals Incorporated, or Vertex.”
FILING10-K0001193125-26-048957cik 0001674416
“We have also established a collaboration and clinical supply agreement with Eli Lilly to evaluate zugo-cel together with pirtobrutinib in aggressive B-cell lymphomas, further expanding the program's development in oncology.”
FILING10-K0001193125-26-048957cik 0001674416
Watchlist prices, news filtered to it, and its next report on your desk.
CRISPR Therapeutics AG has 1 disclosed supplier and 4 disclosed customers. Each one is named in an SEC filing, either CRISPR Therapeutics AG’s own annual report or the counterparty’s, and carries the sentence that discloses it.
CRISPR Therapeutics AG
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
CRSP (CRISPR Therapeutics AG) has 1 disclosed suppliers and 4 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: ACET −15.62%, in healthcare.